Project Grant R01CA308363
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $698K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
College Park, MD 20742, USA
Similar Awards
- The National Cancer Institute awarded the University of Maryland, College Park $663,736 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a multimodal KeyScope laparoscope that increases access to laparoscopic surgery in underserved settings. The project addresses the gap between the clinical standard of laparoscopic surgery—which reduces post-surgical mortality and morbidity compared to open surgery—and its limited availability in rural...
- The National Cancer Institute awarded the University of Illinois $665,257 on September 3, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop molecular diagnostic methods for cervical cancer screening. The recipient will develop and validate a loop-mediated isothermal amplification (LAMP)-based assay for detecting high-risk human papillomavirus (HPV) infection in cervical samples, designed for point-of-care deployment in low-resource settings where access...
- Federal Project Grant Award Summary New York University received a $442,750 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), with performance extending from September 23, 2025 through August 31, 2027. This research initiative delivers a systematic, theory-driven analysis of implementation strategies for cervical cancer control policies in African low- and middle-income countries (LMICs). The project employs a rigorous...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $498,565 Project Grant to The University of Texas MD Anderson Cancer Center on September 8, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a Globally Accessible and Pragmatic Predictive Signature (GAPPS) for locally advanced cervical cancer. The project, which extends through July 31, 2029, addresses a critical clinical need to risk-stratify cervical cancer patients undergoing...
- Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...
- The National Cancer Institute awarded the University of California, Los Angeles $446,900 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to optimize geographic expansion of cervical cancer screening and treatment in remote and rural settings. The recipient will develop a scientific framework to identify optimal strategies for expanding cervical cancer screening access under resource constraints, designed to assist the Indian Health Service, the Alaska...
- The National Cancer Institute awarded Weill Medical College of Cornell University $702,461 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate a novel educational intervention designed to improve timely colposcopy follow-up and treatment among high-risk populations with abnormal cervical cancer screening results. The funded project conducts a hybrid implementation-effectiveness trial testing the COLPO (Clear Communication, Optimize Follow Up,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a Project Grant of $376,490 under the Cancer Treatment Research program (CFDA 93.395) beginning July 1, 2025 and concluding June 30, 2027. This award supports research and development of a novel therapeutic combination strategy targeting cervical cancer through the integration of a C-MYC inhibitor (MYCI975) with SHETA2, an investigational heat shock protein inhibitor...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $3,112,535 on September 15, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a pilot phase IIA randomized placebo-controlled trial evaluating the safety, adherence, and preliminary efficacy of adjuvant 5-fluorouracil (5FU) as an intravaginal therapy following thermal ablation for cervical precancer treatment in women living with HIV in Kenya. The project addresses high...
- This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...